Novo Nordisk introduces NovoCare Pharmacy for Wegovy
With shortages of its blockbuster obesity now declared resolved in the USA, Denmark’s Novo Nordisk (NOV: N) is moving to make the drug more widely available.
As part of its ongoing efforts to ensure patients who need Wegovy (semaglutide) injection 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg can access it, Novo Nordisk launched NovoCare Pharmacy, a direct-to-patient delivery option that offers cash-paying patients all dose strengths of Wegovy at a reduced cost of $499 per month.
The move follows a similar decision announced last month by US pharma major Eli Lilly (NYSE: LLY) for its rival obesity treatment Zepbound (tirzepatide), when it launched 7.5mg and 10mg Zepbound single-dose vials for the treatment of obesity for between $349 and $499 per month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze